Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 25;10(10):2390.
doi: 10.3390/biomedicines10102390.

Correlation between Retinal Vascularization and Disease Aggressiveness in Amyotrophic Lateral Sclerosis

Affiliations

Correlation between Retinal Vascularization and Disease Aggressiveness in Amyotrophic Lateral Sclerosis

Gilda Cennamo et al. Biomedicines. .

Abstract

Abnormalities in retinal vascularization and neural density have been found in many neurodegenerative diseases; however, conflicting results are described in Amyotrophic Lateral Sclerosis (ALS). The aim of the present study was, therefore, to systematically analyze retinal layers and vascularization by means of spectral-domain (SD-OCT) and optical coherence tomography angiography (OCT-A) in ALS patients. We enrolled 48 ALS patients and 45 healthy controls. ALS patients were divided into three groups: slow progressors (n = 10), intermediate progressors (n = 24) and fast progressors (n = 14), according to the disease progression rate. For SD-OCT, we evaluated the Subfoveal choroidal thickness (SFCT), ganglion cell complex (GCC) and retinal nerve fiber layer (RNFL). Regarding the OCT-A, we assessed the vessel density (VD) in superficial and deep capillary plexuses, radial peripapillary capillary plexus, choriocapillary and the foveal avascular zone (FAZ) area. SD-OCT exam did not show any significant differences in GCC and RNFL thickness between patients and controls and among the three ALS groups. The SFCT was statistically greater in patients compared with controls (357.95 ± 55.15 µm vs. 301.3 ± 55.80 µm, p < 0.001); interestingly, the SFCT was thicker in patients with slow and intermediate disease progression than in those with fast disease progression (394.45 ± 53.73 µm vs. 393.09 ± 42.17 µm vs. 267.71 ± 56.24 µm, p < 0.001). OCT-A did not reveal any significant results. Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-r) and disease duration did not correlate with any of the OCT parameters, except for SFCT with ALSFRS-r (r = 0.753, p = 0.024). This study demonstrated the possible association between choroidal thickness and disease activity in ALS. OCT could be a useful biomarker in the management of the disease.

Keywords: ALS; OCT; angiography; biomarker; choroid; disease progression; eye; inflammation; retinal nerve fiber layer; vascular.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses or interpretation of data, in the writing of the manuscript or in the decision to publish the results.

Figures

Figure 1
Figure 1
Spectral domain optical coherence tomography (SD-OCT) images from a healthy subject’s right eye (male, 58 years) with normal thicknesses of ganglion cell complex (GCC) (A) and retinal nerve fiber layer (RNFL) (B). The OCT B-scan shows normal retinal and choroidal thickness (C). Patient’s right eye (female, 60 years) affected by amyotrophic lateral sclerosis (ALS) with slow disease progression. SD-OCT shows normal GCC and RNFL thickness (A1,B1). The OCT B-scan shows normal retinal thickness and a thicker choroid (C1). Patient’s right eye (female, 61 years) affected by ALS with intermediate disease progression. SD-OCT shows normal GCC and RNFL thickness (A2,B2). The OCT B-scan shows normal retinal thickness and an increased choroidal thickness (C2). The bottom row reveals a patient’s left eye (female, 57 years) affected by ALS with fast disease progression. SD-OCT shows normal GCC and RNFL thickness (A3,B3). The OCT B-scan shows normal retinal and a thinner choroid (C3).
Figure 2
Figure 2
OCT-A from a healthy subject’s right eye (male, 58 years) shows normal vasculature texture in macular region (retinal superficial, deep capillary plexuses and in coriocapillary) and in papillary region (AC,E). The foveal avascular zone (FAZ) area shows a normal size (D). The second row shows the patient’s right eye (female, 60 years) affected by amyotrophic lateral sclerosis (ALS) with slow disease progression. OCT-A images reveal absence of abnormalities in retinal and choriocapillary vascular plexuses in macular and papillary regions (A1,B1,C1,E1). The FAZ shows a normal area (D1). The third row shows a patient’s left eye (female, 61 years) affected by ALS with intermediate disease progression. OCT-A reveals absence of abnormalities in retinal and choriocapillary vascular plexuses in macular and papillary regions (A2,B2,C2,E2). The FAZ shows a normal area (D2). The bottom row reveals the patient’s left eye (female, 57 years) affected by ALS with fast disease progression. OCT-A images show normal retinal and choriocapillary vascular plexuses in macular and papillary regions (A3,B3,C3,E3). The FAZ shows a normal area (D3).

Similar articles

Cited by

References

    1. Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098. doi: 10.1016/S0140-6736(17)31287-4. - DOI - PubMed
    1. Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733–748. doi: 10.1002/med.21528. - DOI - PubMed
    1. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585–591. doi: 10.1056/NEJM199403033300901. - DOI - PubMed
    1. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996;347:1425–1431. doi: 10.1016/S0140-6736(96)91680-3. - DOI - PubMed
    1. Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310. - DOI - PMC - PubMed

LinkOut - more resources